Last Update 31 Jul 26
Fair value Increased 12%MMSI: Strong Q2 Execution And 2026 Guidance Will Test Earnings Power
Merit Medical Systems' analyst fair value estimate has increased from $74.00 to $83.00, in line with higher Street price targets after analysts highlighted a strong Q2 report, a rebound in organic growth, raised 2026 guidance and expectations for improved margins and earnings power.
Analyst Commentary
The recent research coverage on Merit Medical Systems centers on a stronger Q2 print, higher 2026 guidance and a series of upward price target revisions. Analysts generally view the quarter as supportive of improved earnings power, with commentary pointing to organic growth momentum and room for margin improvement and free cash flow generation.
Several firms lifted their price targets into a higher valuation range following the Q2 report. Targets now span from US$95 to US$114, including a higher target from JPMorgan, which keeps an Overweight rating on the stock. Across this group, the common thread is that Merit Medical Systems is seen as executing well on its current plan, with raised medium term guidance reinforcing that message.
At the same time, not all of this is framed as a simple upside story for investors. As targets move higher, they also set a higher bar for execution, particularly into 2026, when management guidance becomes a key reference point for judging whether Merit Medical Systems is tracking in line with expectations.
Bearish Takeaways
- Bearish analysts may see the cluster of higher targets, including the US$114 high end, as compressing the margin of safety if the stock trades closer to these levels without a matching step up in fundamentals.
- The emphasis on a sharp rebound in organic growth and potential margin leverage could become a risk if execution falls short of current 2026 guidance, which would challenge the earnings power now embedded in these targets.
- With several firms highlighting expectations for sustained strong revenue growth and free cash flow, any slowdown or volatility in quarterly results could prompt valuation resets from currently optimistic scenarios.
- JPMorgan and other major firms keeping positive ratings while lifting targets raises the hurdle for future quarters, since even small missteps on growth or profitability may carry more downside risk than before for Merit Medical Systems.
What’s in the News for Merit Medical Systems
- Merit Medical Systems raised its 2026 guidance, with total revenue now expected in a range of US$1.631b to US$1.643b, compared with prior guidance of US$1.612b to US$1.634b. The company referenced stronger than expected first half 2026 results, improving profitability and solid cash flow generation. Source: Company guidance update.
- The company initiated a voluntary Class II recall of certain Splashwire Hydrophilic Guide Wire products due to unsealed portions of pouches, affecting 5,004 devices distributed across the U.S. and multiple international markets. The recall status is described as ongoing. Source: U.S. FDA enforcement report.
- Merit Medical Systems initiated a voluntary Class II recall of the Philips Bridge Prep Kit REF K12-09098C because the catheter may experience resistance when advanced over the guidewire, with all lots under UDI 00884450816509 included and distribution reported in Colorado. Source: U.S. FDA enforcement report.
- The U.S. FDA reported a separate Class II recall for the Philips Bridge Prep Kit REF K12-09098B, with all lots under UDI 00884450771310 included and citing the same guidewire resistance issue. The event is described as voluntary and firm initiated, with distribution in Colorado. Source: U.S. FDA enforcement report.
- On May 14, 2026, Merit Medical Systems adopted Fifth Amended and Restated Bylaws that update rules for remote participation in shareholder and Board meetings, electronic delivery of meeting notices, universal proxy provisions, officer composition, certificated and uncertificated shares, and indemnification in line with the Utah Revised Business Corporation Act. Source: Company corporate governance filing.
Valuation Changes for Merit Medical Systems
- Fair Value has risen from $74.00 to $83.00, which represents an increase of about 12% in the analyst fair value estimate for Merit Medical Systems.
- Discount Rate has moved from 8.22% to 7.66%, a modest reduction that results in a slightly lower required return in the valuation model.
- Revenue Growth has shifted from 5.86% to 6.13%, reflecting a small upward adjustment to expected dollar revenue expansion used in the analysis.
- Net Profit Margin has changed from 11.48% to 11.93%, indicating a minor increase in the projected share of dollar revenue that turns into profit.
- Future P/E has been adjusted from 27.13x to 28.08x, which points to a slightly higher earnings multiple applied to Merit Medical Systems in forward-looking assumptions.
Catalysts
About Merit Medical Systems
Merit Medical Systems develops and sells medical devices used in vascular, oncology, cardiac, renal and endoscopy procedures worldwide.
What are the underlying business or industry changes driving this perspective?
- Although the acquisition of View Point Medical expands the breast and soft tissue localization offering and triples the addressable biopsy procedure opportunity, integration risk and the initial non-GAAP EPS dilution of around $0.05 in 2026 could limit how much of that larger procedure pool converts into revenue and earnings growth.
- While demand for less invasive oncology and endoscopy procedures and products like SCOUT, OneMark and the Resilience esophageal stent aligns with long term trends in cancer detection and treatment volumes, adoption curves, clinician training needs and possible product overlap may slow the expected lift to therapeutic revenue and constrain margin mix benefits.
- Although the company outlines long term product platforms in areas such as vascular intervention, cardiac therapies, renal therapies and OEM, and references multiyear growth and profitability targets under CGI, execution on product launches, recalls in renal and OEM order volatility could weigh on revenue growth and keep operating margins closer to current levels rather than expanding quickly.
- While the shift to a clearer foundational and therapeutic revenue framework and eight platform model is meant to sharpen internal focus, the need to keep investing in SG&A and R&D to support these platforms, while tariffs of about $15 million are included in 2026 guidance, may cap near term net margin improvement despite current cost discipline.
- Although underlying procedure trends in areas like vascular access and cardiac care support demand for both foundational and therapeutic products, exposure to volume based purchasing in China, macro related softness in APAC OEM demand and geopolitical freight pressures could temper international revenue growth and keep earnings progress more gradual than hoped.
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more pessimistic perspective on Merit Medical Systems compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
- The bearish analysts are assuming Merit Medical Systems's revenue will grow by 6.1% annually over the next 3 years.
- The bearish analysts assume that profit margins will increase from 9.2% today to 11.9% in 3 years time.
- The bearish analysts expect earnings to reach $225.1 million (and earnings per share of $3.45) by about July 2029, up from $145.6 million today. The analysts are largely in agreement about this estimate.
- In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 28.1x on those 2029 earnings, down from 34.9x today. This future PE is lower than the current PE for the US Medical Equipment industry at 28.8x.
- The bearish analysts expect the number of shares outstanding to grow by 0.78% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.66%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Rising and potentially changing tariff regimes on imports, with US$15 million of tariff expense included in 2026 guidance and uncertainty around future policy and refunds, could pressure gross margin if reimbursement is delayed or if additional tariffs or retaliatory actions are introduced. This would filter through to operating margin and net income.
- Longer term exposure to geopolitical and freight disruptions, including the cited Middle East shipping issues that already prevented about US$1.5 million of revenue from being recognized in one quarter and recurring fuel surcharges, could keep logistics costs elevated and periodically interrupt deliveries. This could weigh on international revenue and compress operating margin.
- OEM demand volatility, with a 14% year over year OEM revenue decline in Q1 and ongoing macro softness in APAC and inventory destocking in the U.S., highlights the risk that this segment remains lumpy rather than settling into the targeted mid to high single digit profile. This would drag on total revenue growth, mix and therefore company wide margins and earnings.
- Product and supply chain issues, including the recent renal product recall and earlier endoscopy and cardiac supply constraints, show that quality or manufacturing setbacks can reappear. If similar issues occur in larger platforms such as oncology, endoscopy or vascular intervention, they could interrupt sales momentum, require added remediation spend and pressure both revenue and net margin.
- Execution risk around acquisitions and platform expansion is rising, as the View Point Medical deal is initially dilutive to 2026 non GAAP EPS by about US$0.05 and relies on meaningful growth in products like OneMark and Resilience to justify higher margins and returns. Any shortfall in integration, clinician adoption or cross selling would reduce the expected uplift to revenue, gross margin and long term earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bearish price target for Merit Medical Systems is $83.0, which represents up to two standard deviations below the consensus price target of $97.0. This valuation is based on what can be assumed as the expectations of Merit Medical Systems's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $114.0, and the most bearish reporting a price target of just $83.0.
- In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $1.9 billion, earnings will come to $225.1 million, and it would be trading on a PE ratio of 28.1x, assuming you use a discount rate of 7.7%.
- Given the current share price of $85.01, the analyst price target of $83.0 is 2.4% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Merit Medical Systems?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
